Lumida
/LAB
⌘K
Standard BioTools Inc

Standard BioTools Inc

LAB
$0.89USD↑+4.36%+0.04 today

MARKET CAP

350.3M

P/E (TTM)

4.5x

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$2

AI Summary

Stalk
Sell NowHigh

In this Stage 4 decline, price has broken key support with a Support Failure pattern, and short-term and long-term trends remain down. Despite extreme oversold conditions, there are no signs of stabilization or institutional demand, with declining EMAs acting as resistance. Execution posture is bearish with the medium-term tradable side permitting a sell into rallies. Given unfavorable timing conditions for entering new bearish positions, execution should occur now on any relief bounce into EMAs or resistance areas.

  • ↑Achieved $50M of $80M synergy goal by end-2024, boosting cost efficiency.
  • ↑Consumables revenue grew 10% in Q4, driven by SomaScan kit sales.
  • ↓Q1 2025 revenue declined 10% YoY to $40.8M, reflecting headwinds.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Standard BioTools Inc. (NASDAQ: LAB) is a notable player in the life sciences sector, specializing in the development of innovative solutions aimed at enhancing biological discovery and precision medicine. Following its merger with Somalogic, the company is pivoting towards expanding its presence in the proteomics market with its SomaScan technology. This strategic merger combined with a focus on multi-omics solutions positions Standard BioTools to capitalize on growth in a dynamic and evolving biotech ecosystem.

Bull says

  • ↑Achieved $50M of $80M synergy goal by end-2024, boosting cost efficiency.
  • ↑Consumables revenue grew 10% in Q4, driven by SomaScan kit sales.
  • ↑Illumina partnership set to launch proteomics platform in early 2025.
  • ↑Analysts have raised earnings forecasts, signaling growing confidence.
  • ↑Targets adjusted EBITDA breakeven by 2026 via aggressive cost cuts.
  • ↑Strong balance sheet with $261M cash provides ample runway.

Bear says

  • ↓Q1 2025 revenue declined 10% YoY to $40.8M, reflecting headwinds.
  • ↓Gross margin fell to 53.2% from 56.2% YoY, squeezing profits.
  • ↓$73M cash burn in Q4 integration raises liquidity concerns.
  • ↓High customer concentration creates volatility if big clients pull back.
  • ↓Capital‐spending constraints and potential NIH funding cuts weigh on demand.
  • ↓Weak profitability factors and negative earnings yield deter investors.

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 06-30-2026bullish

Transcript signals

Bull points

  • in the first quarter, our pro forma combined revenue was just over $46 million. It grew about 2%, largely in line with expectations, and again, all while continuing to navigate the lingering headwinds from a challenging macroeconomic environment.
  • The SomaScan-related business contributed about $24 million in revenue for the quarter, grew over 20%, and that's on healthy demand from SomaScan customers, growth in our kits business to authorized sites, and the initiation of the early access program with Illumina, which, as Michael mentioned, is on track for a full commercial launch in 2025.
  • We broke out that target reduction as follows, $40 million in G&A, $20 million R&D, and $20 million in sales and marketing costs. We also previously announced that we expect to achieve the full $80 million in annualized cost synergies by fiscal 26, and that we would have at least 50% or $40 million of that operationalized in 2024, with the full P&L impact of those savings reflected in 25.

Bear points

  • revenues were 22 million, down 12% over last year, and that's due primarily to the lingering economic headwinds we mentioned, most notably impacting capital budgets in both biopharma, academic research, as well as continuing pressure outside the US.
  • We expect this could continue to create pressure throughout 2024, but we continue to remain confident in our ability to drive our non-GAAP gross margins into the mid-60s over time.
  • As our peers have discussed this quarter, it remains a challenging market for capital equipment sales in life sciences, perhaps one of the most challenging in the last decade.
Read full transcript analysis ›